Literature DB >> 11520088

Survival after pancreaticoduodenectomy for periampullary adenocarcinoma: an update.

R C van Geenen1, T M van Gulik, G J Offerhaus, L T de Wit, O R Busch, H Obertop, D J Gouma.   

Abstract

AIM: Survival after pancreaticoduodenectomy for periampullary tumours is limited. Over the last decade peri-operative management has improved and morbidity and mortality decreased. The aim of the study was to analyse recent survival data after pancreaticoduodenectomy and to determine factors that influence survival.
METHODS: From October 1992 to September 1998, 204 patients with a ductal adenocarcinoma in the pancreatic head (108), distal bile duct (32), and ampulla (64) who underwent standard pancreaticoduodenectomy, were analysed with regard to histology and tumour status. Survival was calculated by using the Kaplan-Meier method. Risk factors were identified in a univariate and multivariate analysis.
RESULTS: Median survival after resection for carcinoma of the pancreatic head, distal bile duct, and ampulla were 16, 25 and 24 months, respectively (P=0.008). In the univariate analysis vein resection, blood transfusion of more than four packed red cells, the presence of tumour positive resection margins, lymph-node metastases and poor tumour differentiation significantly decreased survival. In the multivariate analysis positive resection margins, lymph-node metastases, and poor tumour differentiation independently influenced survival.
CONCLUSIONS: Resection margins, lymph-node status and tumour differentiation are independent prognostic factors. Survival after standard pancreaticoduodenectomy for periampullary tumours has not improved. Copyright 2001 Harcourt Publishers Limited.

Entities:  

Mesh:

Year:  2001        PMID: 11520088     DOI: 10.1053/ejso.2001.1162

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  22 in total

1.  Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP).

Authors:  Krishna V Menon; Dhanwant Gomez; Andrew M Smith; Alan Anthoney; Caroline S Verbeke
Journal:  HPB (Oxford)       Date:  2009-02       Impact factor: 3.647

2.  Tumour origin and R1 rates in pancreatic resections: towards consilience in pathology reporting.

Authors:  Munita Bal; Swapnil Rane; Sanjay Talole; Mukta Ramadwar; Kedar Deodhar; Prachi Patil; Mahesh Goel; Shailesh Shrikhande
Journal:  Virchows Arch       Date:  2018-08-08       Impact factor: 4.064

3.  Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness.

Authors:  Stefan Heinrich; Gerhard W Goerres; Markus Schäfer; Markus Sagmeister; Peter Bauerfeind; Bernhard C Pestalozzi; Thomas F Hany; Gustav K von Schulthess; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

4.  Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection.

Authors:  Hartwig Riediger; Frank Makowiec; Eva Fischer; Ulrich Adam; Ulrich T Hopt
Journal:  J Gastrointest Surg       Date:  2006 Sep-Oct       Impact factor: 3.452

5.  Symptom profiles and palliative care in advanced pancreatic cancer: a prospective study.

Authors:  Knut Jørgen Labori; Marianne Jensen Hjermstad; Torunn Wester; Trond Buanes; Jon Håvard Loge
Journal:  Support Care Cancer       Date:  2006-04-07       Impact factor: 3.603

6.  Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma.

Authors:  D Santini; G Tonini; F M Vecchio; D Borzomati; B Vincenzi; S Valeri; A Antinori; F Castri; R Coppola; P Magistrelli; G Nuzzo; A Picciocchi
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

7.  A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma.

Authors:  Russell Lewis; Jeffrey A Drebin; Mark P Callery; Douglas Fraker; Tara S Kent; Jenna Gates; Charles M Vollmer
Journal:  HPB (Oxford)       Date:  2012-09-24       Impact factor: 3.647

8.  Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets.

Authors:  Riccardo Casadei; Mariacristina Di Marco; Claudio Ricci; Donatella Santini; Carla Serra; Lucia Calculli; Marielda D'Ambra; Alessandra Guido; Antonio Maria Morselli-Labate; Francesco Minni
Journal:  J Gastrointest Surg       Date:  2015-07-30       Impact factor: 3.452

9.  Results of vascular resections during pancreatectomy from two European centres: an analysis of survival and disease-free survival explicative factors.

Authors:  M Adham; D F Mirza; F Chapuis; A D Mayer; S R Bramhall; C Coldham; J Baulieux; J Buckels
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

10.  Long-term survival and prognostic indicators in small (<or=2 cm) pancreatic cancer.

Authors:  Supot Pongprasobchai; Rahul Pannala; Thomas C Smyrk; William Bamlet; Suresh Pitchumoni; Andrei Ougolkov; Mariza de Andrade; Gloria M Petersen; Suresh T Chari
Journal:  Pancreatology       Date:  2008-10-13       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.